跳至主要内容
临床试验/NCT06242782
NCT06242782尚未招募3 期

Vertical Ridge Augmentation Strategies: An Adaptive Randomised Controlled Clinical Trial

University College, London0 个研究点目标入组 148 人开始时间: 2024年2月最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
148
主要终点
Incidence of complications

研究概览

简要总结

Guided Bone Regeneration (GBR) is an invaluable and beneficial surgical technique adopted when there is the need to augment an alveolar atrophy. Strong clinical and histologic evidence exists on the effectiveness and predictability of GBR in bone augmentation of ridge deficiencies. On the other hand, it is well known that GBR remains a challenge as in the most extreme cases, it is considered a highly technique-sensitive surgical procedure.

Whilst there are numerous reviews which report the average incidence of complications in GBR, there is still insufficient evidence and manuscripts reporting a direct correlation between a specific biomaterial (membrane or scaffold) and observed complications. Only one recent systematic review and meta-analysis focused on wound healing complications following GBR for ridge augmentation procedures. Authors explored the complication rate based on the membrane type and on the timing of the first sign of soft tissue complications following bone augmentation procedures. They reported a complication rate of 17% of the overall soft tissue complications, including membrane exposure, soft tissue dehiscence, and acute infection (abscess). This estimate is consistent with that reported (12%) in a more recent systematic appraisal of the evidence on all types of complications in GBR (3). However, when horizontal augmentation procedures were reviewed, a higher rate (21%) of complications was reported within the first 18 months of a GBR procedure. This estimate was inclusive of all possible biologic complications following GBR whilst the rate of membrane exposure was of 23%.

Vertical bone augmentation represents one of the most challenging bone regenerative procedures in surgical dentistry. This is because of the inherent difficulties of the surgical procedure and the high risk of complications. The primary aim of this procedure is to recreate alveolar bone in a vertical direction (without the support of any pre-existing walls) and enable recreation of a more favourable anatomy for the restoration of the edentulous site.

Evidence on a variety of treatment options has been produced over the last 15 years including distraction osteogenesis, onlay bone grafting, and vertical ridge augmentation (VRA). Systematic reviews evaluating the efficacy of different surgical procedures for VRA either in a staged or a simultaneous fashion, reported a range of vertical bone gain of 2-8 mm. This gain was gradually lost (1.27 to 2.0mm) between 1 to 7 years post-surgery and a wide range of complications (0- 45.5%) has been reported.

The aim of this study is to assess and compare incidence of complications and percentage of vertical bone gain when using four different barrier membranes in combination with 50/50 autogenous and xenogenous bone material in VRA procedures. Secondary aims will be to evaluate and compare early and late soft tissue wound healing, gingival microvasculature and structure, patient reported outcomes and the prevalence of need for further bone augmentation and need for soft tissue grafting. Additionally, this study will also aim to assess and compare histomorphometry and histochemistry analyses of core biopsies obtained before implant placement between the four different barrier membranes.

详细描述

This is a single centre non-inferiority adaptive randomised controlled clinical trial. The primary aim of this study will be:

To assess the clinical composite outcome (incidence of complications and percentage of vertical bone gain) of vertical alveolar bone grafting procedures in patients with vertical ridge deficiencies prior to dental implant placement, using a mix of autogenous and xenogenic particulate bone materials in combination with four different barrier membranes (Titanium (Ti)-Reinforced d-Polytetrafluoroethylene (PTFE) membrane [control group], Ti-Reinforced e-PTFE Membrane, 3D printed Ti-mesh and Reinforced PTFE Mesh (RPM)).

Secondary aims are:

  • To assess and compare soft tissue wound healing and vascularization using Laser Doppler Flowmetry (LDF) between tests and control.
  • To assess and compare gingival microvasculature and structure in vivo using Optical Coherence Tomography (OCT) between tests and control.
  • To compare prevalence of the need for further bone grafting at the time of implant placement between tests and control.
  • To compare prevalence of the need of soft tissue grafting at second stage surgery between tests and controls.
  • To assess and compare patient reported outcomes using the EuroQol five-dimension (EQ-5D-5L) scale and the short-form Oral Health Impact Profile (OHIP-14) between tests and control.
  • To assess and compare histomorphometry and histochemistry analyses of core biopsies obtained from a sample of 5 participants from each group before implant placement between tests and control.

Patients in need of vertical ridge augmentation prior to dental implant placement will be recruited to take part in this study and will be randomised into one of the following groups receiving different interventions:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Partially edentulous with a ridge that shows at least 3mm vertical bone deficiency;
  • Females of childbearing potential and males agree to use an effective method of contraception from the time consent is signed until treatment discontinuation.
  • Females of childbearing potential have a negative pregnancy test within 7 days prior to being registered. Participants are considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
  • Willing and able to provide written informed consent.

排除标准

  • Comorbidities (or regular use of medications)
  • History of bone augmentation or implant placement at the area of interest
  • Females who are pregnant, planning pregnancy or breastfeeding
  • Regular use of analgesic or antibiotics within 1 month before entering the study
  • Disclosed smoking (including electronic cigarettes) or drinking over 14 alcoholic units per week
  • Active oral diseases or poor oral hygiene (defined by full mouth dental plaque scores greater than 25%)
  • Suspected or documented titanium allergy or intolerance
  • Concurrent and/or recent involvement in other research that is likely to interfere with the intervention within last 3 months of study enrolment

结局指标

主要结局

Incidence of complications

时间窗: Baseline visit (day 0) and follow up visits (at days 1, 4(±1), 7(±1), 15(±1), 30(±3), 60(±7) and 120(±7) post surgical VRA and at days 7(±1), 15(±1), 30(±7), 90(±7), 120(±7), 180 (±14) and 365 (±14) post dental implant placement

Measured by clinical observation/examination at each follow up visit following VRA surgery.

Percentage of vertical bone gain

时间窗: At baseline (before surgical VRA) and at time of dental implant(s) placement (not earlier than 180 days post surgical VRA)

Measured on cone beam computed tomography (CBCT).

次要结局

  • Soft tissue vascularization and wound healing(Baseline visit (day 0) and follow up visits (at days 1, 4(±1), 7(±1), 15(±1), 30(±3), 60(±7) and 120(±7) post surgical VRA and at days 7(±1), 15(±1), 30(±7), 90(±7), 120(±7), 180 (±14) and 365 (±14) post dental implant placement)
  • Gingival microvasculature and structure in vivo(Baseline visit (day 0) and follow up visits (at days 1, 4(±1), 7(±1), 15(±1), 30(±3), 60(±7) and 120(±7) post surgical VRA and at days 7(±1), 15(±1), 30(±7), 90(±7), 120(±7), 180 (±14) and 365 (±14) post dental implant placement)
  • Histomorphometry analysis(At time of dental implant(s) placement (not earlier than 180 days post surgical VRA))
  • Histochemistry analysis(At time of dental implant(s) placement (not earlier than 180 days post surgical VRA))
  • Need of soft tissue grafting(At time of dental implant(s) placement (not earlier than 180 days post surgical VRA))
  • Need for additional bone grafting(At time of dental implant(s) placement (not earlier than 180 days post surgical VRA))
  • Patient reported outcome measures(Baseline visit (day 0) and follow up visits (at days 1, 4(±1), 7(±1), 15(±1), 30(±3), 60(±7) and 120(±7) post surgical VRA and at days 7(±1), 15(±1), 30(±7), 90(±7), 120(±7), 180 (±14) and 365 (±14) post dental implant placement)

研究者

申办方类型
Other
责任方
Sponsor

相似试验